Patient-specific Induced Pluripotent Stem Cells as a Platform for Disease Modeling, Drug Discovery and Precision Personalized Medicine
- Corresponding Author:
- Christoph Schaniel
Department of Developmental and Regenerative Biology
Mount Sinai School of Medicine
New York, NY, USA
E-mail: [email protected]
Received Date: July 13, 2012; Accepted Date: September 17, 2012; Published Date: September 19, 2012
Citation: Young W, D’Souza SL, Lemischka IR, Schaniel C (2012) Patientspecific Induced Pluripotent Stem Cells as a Platform for Disease Modeling, Drug Discovery and Precision Personalized Medicine. J Stem Cell Res Ther S10:010. doi:10.4172/2157-7633.S10-010
Copyright: © 2012 Young W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The breakthrough development of induced pluripotent stem cell (iPSC) technology is not only revolutionizing basic stem cell science but is also spurring efforts to reprogram one somatic cell type directly into another. Induced pluripotent stem cells provide scientists with a self-renewing and, thus, unlimited, source of pluripotent cells for targeted differentiation, in principle, into the entire range of cell types found in the body. Therefore, iPSC technology and the increasingly refined abilities to differentiate iPSCs into disease-relevant mature cells has far reaching implications for understanding disease etiology and promoting drug discovery and other advances in regenerative medicine. In this review, we summarize the latest progress in the application of patient-specific iPSCs for disease modeling, drug screening and cell replacement therapy, and discuss their impact on precision personalized medicine.